middle.news
How Neurotech’s NTI164 Is Poised to Transform Pediatric Neurological Care
9:22am on Thursday 31st of July, 2025 AEST
•
Healthcare
Read Story
How Neurotech’s NTI164 Is Poised to Transform Pediatric Neurological Care
9:22am on Thursday 31st of July, 2025 AEST
Key Points
Positive Phase I human pharmacokinetic study confirms NTI164 safety and rapid absorption
Published Phase I/II Rett Syndrome trial shows clinical improvements and good tolerability
Dual regulatory pathways progressing with FDA and TGA, preparing IND submission
Appointment of Dr. Bonni Goldstein as Chief Medical Advisor to strengthen US clinical strategy
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NTI
OPEN ARTICLE